Braveheart Bio poised to surge in New York debut after upsized $383 million IPO
06/08/2026 15:49
BUZZ-Braveheart Bio poised to surge in New York debut after upsized $383 million IPO ** Drug developer Braveheart Bio BRVE.O on track to open above offer price in Nasdaq debut after upsized $382.5 million U.S. IPO
** Stock recently indicated to open at $25 apiece vs $18 offer price
** San Francisco, California-based BRVE sold ~21.3 million shares in upsized IPO at $18 apiece
** BRVE, which is developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases, had initially marketed 18.75 million shares priced between $15 and $17
** Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor acted as joint book-running managers for offering
(Reporting by Arasu Kannagi Basil in Bengaluru)
Recent news on Braveheart Bio
See all newsU.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI International
U.S. STOCKS ON THE MOVE-Braveheart Bio, Paysign, Hertz Global
Braveheart Bio surges 70% in cracking New York debut after upsized $383 million IPO
NASDAQ RESUMED AT 12:50 PM
U.S. STOCKS ON THE MOVE-Ralph Lauren, Sempra, Parker-Hannifin, Lincoln International